DB18624InvestigationalCell transplant therapies
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.
- Also known as
- allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
- Code names
- VOR-33
What you can answer from here — as of April 23, 2025
Which companies are running trials of VOR33, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account